Opposite effects of tamoxifen on metabolic syndrome‐induced bladder and prostate alterations: A role for GPR30/GPER?
- 26 August 2013
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 74 (1) , 10-28
Abstract
BACKGROUND: BPH and LUTS have been associated to obesity, hypogonadism, and metabolic syndrome (MetS). MetS‐induced prostate and bladder alterations, including inflammation and tissue remodeling, have been related to a low‐testosterone and high‐estrogen milieu. In addition to ERs, GPR30/GPER is able to mediate several estrogenic non‐genomic actions.METHODS: Supplementing a subgroup of MetS rabbits with tamoxifen, we analyzed the in vivo effects on MetS‐induced prostate and bladder alterations. The effects of selective ER/GPER ligands and GPER silencing on prostate inflammation were also studied in vitro using hBPH cells.RESULTS: ERα, ERβ, and PR expression was upregulated in MetS bladder, where tamoxifen decreased ERα and PR expression, further stimulating ERβ. In addition, tamoxifen‐dosing decreased MetS‐induced overexpression of inflammatory and tissue remodeling genes. In prostate, sex steroid receptors, pro‐inflammatory and pro‐fibrotic genes were upregulated in MetS. However, tamoxifen did not affect them and even increased COX‐2. In hBPH cells, 17β‐estradiol increased IL‐8 secretion, an effect blunted by co‐treatment with GPER antagonist G15 but not by ER antagonist ICI 182,780, which further increased it. GPER agonist G1 dose‐dependently (IC50 = 1.6 nM) induced IL‐8 secretion. In vitro analysis demonstrated that GPER silencing reverted these stimulatory effects.CONCLUSIONS: GPER can be considered the main mediator of estrogen action in prostate, whereas in bladder the mechanism appears to rely on ERα, as indicated by in vivo experiments with tamoxifen dosing. Limiting the effects of the MetS‐induced estrogen action via GPER could offer new perspectives in the management of BPH/LUTS, whereas tamoxifen dosing showed potential benefits in bladder. Prostate 74:10–28, 2014.Keywords
This publication has 90 references indexed in Scilit:
- Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome‐associated prostate alterations: An experimental study in the rabbitThe Prostate, 2012
- Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic reviewBMC Medicine, 2012
- Androgens and estrogens in benign prostatic hyperplasia: Past, present and futureDifferentiation, 2011
- Associations Between Longitudinal Changes in Serum Estrogen, Testosterone, and Bioavailable Testosterone and Changes in Benign Urologic OutcomesAmerican Journal of Epidemiology, 2011
- Farnesoid X Receptor Activation Improves Erectile Function in Animal Models of Metabolic Syndrome and DiabetesThe Journal of Sexual Medicine, 2011
- Serum Steroid and Sex Hormone-Binding Globulin Concentrations and the Risk of Incident Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention TrialAmerican Journal of Epidemiology, 2008
- Development of Diabesity in Mice with Neuronal Deletion of Shp2 Tyrosine PhosphataseThe American Journal of Pathology, 2008
- Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgenJournal of Endocrinology, 2008
- A Dose‐Response Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone UndecanoateJournal of Andrology, 2008
- Relationship of Lifestyle and Clinical Factors to Lower Urinary Tract Symptoms: Results from Boston Area Community Health SurveyUrology, 2007